QR 333

Drug Profile

QR 333

Alternative Names: QR-333

Latest Information Update: 02 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Quigley Pharma
  • Class Analgesics
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 24 Jul 2009 QR 333 is available for licensing (www.quigleyco.com)
  • 22 Jul 2009 A phase IIb trial did not meet primary and secondary endpoints
  • 30 Apr 2009 Efficacy data from a phase IIb trial in Diabetic neuropathies released by Quigley Pharma ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top